Escetamina (Portuguese Wikipedia)

Analysis of information sources in references of the Wikipedia article "Escetamina" in Portuguese language version.

refsWebsite

Global rank Portuguese rank

14nih.gov

4^th place

8^th place

13doi.org

2^nd place

4^th place

4fda.gov

447^th place

869^th place

2medicinescomplete.com

low place

1reuters.com

49^th place

88^th place

1zenodo.org

621^st place

1,847^th place

1springer.com

274^th place

339^th place

1bloomberg.com

99^th place

191^st place

1bbc.com

20^th place

25^th place

1drugs.com

399^th place

289^th place

1janssen.com

low place

1sciencedirect.com

149^th place

155^th place

1worldcat.org

5^th place

1vice.com

175^th place

294^th place

bbc.com

«Anti-depressant spray not recommended on NHS». BBC News. 28 de janeiro de 2020

bloomberg.com

Koons, Cynthia; Edney, Anna (12 de fevereiro de 2019). «First Big Depression Advance Since Prozac Nears FDA Approval.». Bloomberg News. Consultado em 12 de fevereiro de 2019

doi.org

dx.doi.org

Himmelseher S, Pfenninger E. «[The clinical use of S-(+)-ketamine--a determination of its place]». Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie. 33: 764–70. PMID 9893910. doi:10.1055/s-2007-994851
Rakesh G, Pae CU, Masand PS. «Beyond serotonin: newer antidepressants in the future». Expert Review of Neurotherapeutics. 17: 777–790. PMID 28598698. doi:10.1080/14737175.2017.1341310
Lener MS, Kadriu B, Zarate CA. «Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression» (PDF). Drugs. 77: 381–401. PMC 5342919. PMID 28194724. doi:10.1007/s40265-017-0702-8
Himmelseher S, Pfenninger E. «[The clinical use of S-(+)-ketamine--a determination of its place]». Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie (em alemão). 33: 764–70. PMID 9893910. doi:10.1055/s-2007-994851
Ihmsen H, Geisslinger G, Schüttler J. «Stereoselective pharmacokinetics of ketamine: R(–)-ketamine inhibits the elimination of S(+)-ketamine». Clinical Pharmacology and Therapeutics. 70: 431–8. PMID 11719729. doi:10.1067/mcp.2001.119722
Zhang JC, Li SX, Hashimoto K. «R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine». Pharmacology, Biochemistry, and Behavior. 116: 137–41. PMID 24316345. doi:10.1016/j.pbb.2013.11.033
Muller J, Pentyala S, Dilger J, Pentyala S. «Ketamine enantiomers in the rapid and sustained antidepressant effects». Therapeutic Advances in Psychopharmacology. 6: 185–92. PMC 4910398. PMID 27354907. doi:10.1177/2045125316631267
Hashimoto K. «Ketamine's antidepressant action: beyond NMDA receptor inhibition». Expert Opinion on Therapeutic Targets. 20: 1389–1392. PMID 27646666. doi:10.1080/14728222.2016.1238899
Yang B, Zhang JC, Han M, Yao W, Yang C, Ren Q, Ma M, Chen QX, Hashimoto K. «Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression». Psychopharmacology. 233: 3647–57. PMC 5021744. PMID 27488193. doi:10.1007/s00213-016-4399-2
Nishimura M, Sato K. «Ketamine stereoselectively inhibits rat dopamine transporter». Neuroscience Letters. 274: 131–4. PMID 10553955. doi:10.1016/s0304-3940(99)00688-6
Vollenweider FX, Leenders KL, Oye I, Hell D, Angst J. «Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET)». European Neuropsychopharmacology. 7: 25–38. PMID 9088882. doi:10.1016/s0924-977x(96)00042-9
Yang C, Shirayama Y, Zhang JC, Ren Q, Yao W, Ma M, Dong C, Hashimoto K. «R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects». Translational Psychiatry. 5: e632. PMC 5068814. PMID 26327690. doi:10.1038/tp.2015.136
Krystal, JohH.; Abdallah, Chadi G.; Sanacora, Gerard; Charney, Dennis S.; Duman, Ronald S. (6 de março de 2019). «Ketamine: A Paradigm Shift for Depression Research and Treatment». Neuron (em inglês). 101 (5): 774–778. ISSN 0896-6273. doi:10.1016/j.neuron.2019.02.005

drugs.com

«Esketamine». Drugs.com

fda.gov

accessdata.fda.gov

«SPRAVATO™ (esketamine) nasal spray FDA label» (PDF). Food and Drug Administration. 5 de março de 2019. Consultado em 6 de março de 2019
«Esketamine nasal spray» (PDF). FDA. Consultado em 21 de outubro de 2019

fda.gov

Office of the Commissioner. «Press Announcements - FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor's office or clinic». www.fda.gov (em inglês). Consultado em 6 de março de 2019
Psychopharmacologic Drugs Advisory Committee (PDAC) and Drug Safety and Risk Management (DSaRM) Advisory Committee (12 de fevereiro de 2019). «FDA Briefing Document» (PDF). Food and Drug Administration. Consultado em 12 de fevereiro de 2019. Meeting, February 12, 2019. Agenda Topic: The committees will discuss the efficacy, safety, and risk-benefit profile of New Drug Application (NDA) 211243, esketamine 28 mg single-use nasal spray device, submitted by Janssen Pharmaceutica, for the treatment of treatment-resistant depression.

janssen.com

«Janssen Submits Esketamine Nasal Spray New Drug Application to U.S. FDA for Treatment-Resistant Depression». Janssen Pharmaceuticals, Inc.

medicinescomplete.com

«Text search results for esketamine: Martindale: The Complete Drug Reference». MedicinesComplete. London, UK: Pharmaceutical Press. Consultado em 20 de agosto de 2017
«Ketamine Hydrochloride». MedicinesComplete. London, UK: Pharmaceutical Press. 9 de janeiro de 2017. Consultado em 20 de agosto de 2017

nih.gov

ncbi.nlm.nih.gov

Himmelseher S, Pfenninger E. «[The clinical use of S-(+)-ketamine--a determination of its place]». Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie. 33: 764–70. PMID 9893910. doi:10.1055/s-2007-994851
Rakesh G, Pae CU, Masand PS. «Beyond serotonin: newer antidepressants in the future». Expert Review of Neurotherapeutics. 17: 777–790. PMID 28598698. doi:10.1080/14737175.2017.1341310
Lener MS, Kadriu B, Zarate CA. «Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression» (PDF). Drugs. 77: 381–401. PMC 5342919. PMID 28194724. doi:10.1007/s40265-017-0702-8
Himmelseher S, Pfenninger E. «[The clinical use of S-(+)-ketamine--a determination of its place]». Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie (em alemão). 33: 764–70. PMID 9893910. doi:10.1055/s-2007-994851
Ihmsen H, Geisslinger G, Schüttler J. «Stereoselective pharmacokinetics of ketamine: R(–)-ketamine inhibits the elimination of S(+)-ketamine». Clinical Pharmacology and Therapeutics. 70: 431–8. PMID 11719729. doi:10.1067/mcp.2001.119722
Zhang JC, Li SX, Hashimoto K. «R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine». Pharmacology, Biochemistry, and Behavior. 116: 137–41. PMID 24316345. doi:10.1016/j.pbb.2013.11.033
Muller J, Pentyala S, Dilger J, Pentyala S. «Ketamine enantiomers in the rapid and sustained antidepressant effects». Therapeutic Advances in Psychopharmacology. 6: 185–92. PMC 4910398. PMID 27354907. doi:10.1177/2045125316631267
Hashimoto K. «Ketamine's antidepressant action: beyond NMDA receptor inhibition». Expert Opinion on Therapeutic Targets. 20: 1389–1392. PMID 27646666. doi:10.1080/14728222.2016.1238899
Yang B, Zhang JC, Han M, Yao W, Yang C, Ren Q, Ma M, Chen QX, Hashimoto K. «Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression». Psychopharmacology. 233: 3647–57. PMC 5021744. PMID 27488193. doi:10.1007/s00213-016-4399-2
Nishimura M, Sato K. «Ketamine stereoselectively inhibits rat dopamine transporter». Neuroscience Letters. 274: 131–4. PMID 10553955. doi:10.1016/s0304-3940(99)00688-6
Doenicke A, Kugler J, Mayer M, Angster R, Hoffmann P. «[Ketamine racemate or S-(+)-ketamine and midazolam. The effect on vigilance, efficacy and subjective findings]». Der Anaesthesist (em alemão). 41: 610–8. PMID 1443509
Pfenninger E, Baier C, Claus S, Hege G. «[Psychometric changes rwell as analgesic action and cardiovascular adverse effects of ketamine racemate versus s-(+)-ketamine in subanesthetic doses]». Der Anaesthesist (em alemão). 43 Suppl 2: S68-75. PMID 7840417
Vollenweider FX, Leenders KL, Oye I, Hell D, Angst J. «Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET)». European Neuropsychopharmacology. 7: 25–38. PMID 9088882. doi:10.1016/s0924-977x(96)00042-9
Yang C, Shirayama Y, Zhang JC, Ren Q, Yao W, Ma M, Dong C, Hashimoto K. «R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects». Translational Psychiatry. 5: e632. PMC 5068814. PMID 26327690. doi:10.1038/tp.2015.136

reuters.com

«J&J prices ketamine-like depression treatment at $590-$885 for two...». Reuters (em inglês). 3 de março de 2019. Consultado em 7 de março de 2019

sciencedirect.com

Krystal, JohH.; Abdallah, Chadi G.; Sanacora, Gerard; Charney, Dennis S.; Duman, Ronald S. (6 de março de 2019). «Ketamine: A Paradigm Shift for Depression Research and Treatment». Neuron (em inglês). 101 (5): 774–778. ISSN 0896-6273. doi:10.1016/j.neuron.2019.02.005

springer.com

adisinsight.springer.com

«Esketamine - Johnson & Johnson - AdisInsight». Consultado em 7 de novembro de 2017

vice.com

«How Is Esketamine Different from Ketamine?». www.vice.com (em inglês). Consultado em 8 de agosto de 2020

worldcat.org

Krystal, JohH.; Abdallah, Chadi G.; Sanacora, Gerard; Charney, Dennis S.; Duman, Ronald S. (6 de março de 2019). «Ketamine: A Paradigm Shift for Depression Research and Treatment». Neuron (em inglês). 101 (5): 774–778. ISSN 0896-6273. doi:10.1016/j.neuron.2019.02.005

zenodo.org

Lener MS, Kadriu B, Zarate CA. «Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression» (PDF). Drugs. 77: 381–401. PMC 5342919. PMID 28194724. doi:10.1007/s40265-017-0702-8